Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 50 of 8149 results

  1. Neonatal infection: antibiotics for prevention and treatment (NG195)

    This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.

  2. Suspected sepsis: recognition, diagnosis and early management (NG51)

    This guideline covers the recognition, diagnosis and early management of suspected sepsis. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.

  3. Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)

    This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.

  4. Technology appraisal committee

    Details, meeting dates and minutes of the independent technology appraisal committees

  5. Public board meetings

    Our board meetings are open to the public. You can download the agenda, papers and minutes for each meeting.

  6. Public board meetings

    Agenda and papers of the NICE public board meeting on 20 March 2024

  7. ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessment (HTE5)

    Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management....

  8. Technology appraisal data: appraisal recommendations

    Data on the recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

  9. Technology appraisal data: cancer appraisal recommendations

    Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

  10. Our projects and partners

    NICE research projects and partners.

  11. Guides to developing our guidance

    Resources to help organisations who want to help develop NICE guidance

  12. Register as a stakeholder

    Take part in the production of medical technologies guidance.

  13. Interventional procedures advisory committee

    Advises NICE on the formulation of its guidance on the safety and efficacy of interventional procedures.

  14. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.

  15. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)

    Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for visual impairment caused by chronic diabetic macular oedema that has not responded well enough to available treatments in adults.

  16. Dupilumab for treating moderate to severe prurigo nodularis (TA955)

    Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.

  17. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

  18. NICE and health inequalities

    Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged

  19. Medical technologies advisory committee members

    Find out more about the medical technologies advisory committee members by reading their biographies. Dr Jacob Brown (chair) Biography Jacob

  20. Bringing our guidance together by topic

    We're bringing our guidance together by topic, so that it's all in one place, clearer to understand and easier to access. We expect that this will...

  21. Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over (TA956)

    Evidence-based recommendations on etrasimod (Velsipity) for moderately to severely active ulcerative colitis in people aged 16 and over.

  22. Charging for technology appraisals and highly specialised technologies

    Information about charging for our technology appraisal (TA) and highly specialised technologies (HST) assessments.

  23. Changes to charging for Technology Appraisal and Highly Specialised Technologies consultation

    Take part in our consultation: 5 proposals about the way the NICE charges for TAs and HSTs.

  24. Charging procedure: technology appraisal and highly specialised technologies evaluations

    Introduction In accordance with UK Statutory Instrument 2018 No.1322 , NICE must recover its costs for producing Technology Appraisals (TA) or Highly

  25. Charging procedure: technology appraisal and highly specialised technologies evaluations

    Introduction In accordance with UK Statutory Instrument 2018 No.1322 , NICE must recover its costs for producing Technology Appraisals (TA) or Highly

  26. 25,000 people to benefit after NICE recommends new ulcerative colitis treatment

    New one-a-day pill recommended on the same day the treatment was granted a licence by the MHRA

  27. Board, executive team and senior leaders interests register

    This register shows current declarations of interest made by our: non-executive directors executive team members senior leaders. We publish it

  28. Women inspiring inclusion in NICE guidance

    This International Women’s Day, we’re specifically focusing on the invaluable contributions of two of the women who help shape our guidance through their independent / voluntary committee roles. Hear from them, as they talk about their involvement with NICE and what #InspireInclusion means to them.

  29. Resource planner

    Our tool to help you plan for and implement NICE guidance. View upcoming guidance and understand the impact of guidance on your resources.

  30. Lung cancer: diagnosis and management (NG122)

    This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.

  31. Board

    Our board sets out our strategic priorities and policies.

  32. Resource impact of NICE guidance

    We estimate the costs or savings (budget impact) associated with technologies and guidelines so you can plan for and implement guidance.

  33. Patient Access Schemes Liaison Unit

    The Patient Access Schemes Liaison Unit (PASLU) works with companies who are considering a patient access scheme for their drug or treatment. Patient

  34. Medical technologies advisory committee

    Information, meeting dates and minutes of the medical technologies advisory committee

  35. Technology appraisal and highly specialised technologies appeals

    Technology appraisal and Highly specialised technologies appeals

  36. Digital technologies for delivering multidisciplinary weight-management services: early value assessment (HTE14)

    Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services....

  37. NICE publishes final draft guidance on Enhertu after commercial discussions conclude without a price to make it a cost-effective use of NHS resources.

    NICE has published final draft guidance that does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.

  38. Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)

    This guideline covers recognising, diagnosing and managing vitamin B12 deficiency in people aged 16 and over, including deficiency caused by autoimmune gastritis. It also covers monitoring for gastric cancer in people with autoimmune gastritis.

  39. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)

    Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

  40. Get involved

    We want you to tell us what matters to you, your organisation or your community.

  41. NICE training and development opportunities

    To help us understand the needs of our users we are offering the opportunity to be directly involved in the work we do. Fellows, registrars and...

  42. How to apply to join a committee

    We're excited that you're interested in joining a committee and helping us improve health and social care services. By joining, you'll have the...

  43. Digital technologies for managing non-specific low back pain: early value assessment (HTE16)

    Early value assessment (EVA) guidance on digital technologies for managing non-specific low back pain in people 16 years and over....

  44. New treatment option available today for womb cancer

    A new treatment option given with chemotherapy is recommended for some types of advanced or recurrent womb cancer in final draft NICE guidance published today.

  45. Admission rates due to heart failure in people with diabetes

    Admission rates due to heart failure in people with diabetes Subject(s): Diabetes Date of publication: 01 August

  46. What professional members do

    All our committees include experienced professionals with knowledge of a particular topic within health or social care . Professional members also...

  47. Our committees

    Find out more about being on a committee at NICE.

  48. A public consultation on our new approach to prioritising guidance is now open

    Running for 4 weeks, the consultation seeks your views about our plans to make topic selection and prioritisation more integrated, effective and timely.

  49. Life sciences: how to get your product to market

    Support for industry to engage with NICE during all stages of health technology development

  50. Achieving and demonstrating compliance with NICE TA and HST guidance

    The NHS and patients need evidence that commissioners are funding medicines and treatments approved through the NICE Technology Appraisal (TA) or...